Quoted from http://online.wsj.com/article/BT-CO-20130314-709260.html
FDA Conducting Safety Review Of Certain Diabetes Drugs
By Jennifer Corbett Dooren
- March 14, 2013, 11:46 a.m. ET
WASHINGTON--The U.S. Food and Drug Administration Thursday said it is reviewing information about a class of diabetes drugs that suggests they might cause pre-cancerous changes in the pancreas.
Such drugs involve newer types of Type 2 diabetes medicines that include Bristol-Myers Squibb Co.'s (BMY) Byetta, Bydureon and Onglyza; Novo Nordisk A/S's (NVO) Victoza; Merck & Co.'s (MRK) Januvia; and Eli Lilly & Co.'s (LLY) Tradjenta. The pancreas is a gland that produces several hormones and enzymes, including insulin.
The labels on the drugs currently warn of an increased risk of pancreatitis, or inflammation of the pancreas, but the suggestion of pre-cancerous changes in the pancreas is new. However, the FDA stressed that it hasn't concluded that the medicines "may cause or contribute to the development of pancreatic cancer."
[Article continues at original source]